Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

Opinion|Videos|December 21, 2023

Enfortumab Vedotin and the Role of ADCs in Bladder Cancer

Author(s)Axel Merseburger, MD, PhD, M. Carmen Mir, MD, PhD, Shilpa Gupta, MD

Bladder cancer specialists discuss enfortumab vedotin and the role of antibody-drug conjugates in the treatment landscape.

Episodes in this series

A panel of 4 experts on bladder cancer seated at a long table

EP. 1 Overview of Non–Muscle Invasive Bladder Cancer (NMIBC)

A panel of 4 experts on bladder cancer seated at a long table

EP. 2 Treatment Considerations and Role of Trimodal Therapy in Bladder Cancer

A panel of 4 experts on bladder cancer seated at a long table

EP. 3 Monitoring Patients With NMIBC

A panel of 4 experts on bladder cancer seated at a long table

EP. 4 Bladder Cancer: Treatment Options and Managing Adverse Effects

A panel of 4 experts on bladder cancer seated at a long table

EP. 5 Bladder Cancer: Highlights from ESMO 2023 and Ongoing Developments

A panel of 5 experts on bladder cancer

EP. 6 Enfortumab Vedotin and the Role of ADCs in Bladder Cancer

A panel of 5 experts on bladder cancer

EP. 7 Approach to Collaborative Care in Bladder Cancer

A panel of 4 experts on bladder cancer seated at a long table

EP. 8 Key Takeaways on Evolving Bladder Cancer Treatment Landscape

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Laura Bukavina, MD, discusses debate on high-grade tumor risk stratification

ByLaura Bukavina, MD, MPH, MSc

December 13th 2025

EMA recommends conditional approval of Anktiva in BCG-unresponsive NMIBC

ByHannah Clarke

December 12th 2025

Fed Ghali, MD on key unanswered questions with perioperative EV/pembro

ByFed Ghali, MD

December 11th 2025

2025 year in review: Breakthroughs in urologic oncology during a year of unprecedented awareness

ByMichael S. Cookson, MD, MMHC, FACS

December 10th 2025

Gal Wald, MD on PROs from phase 2 gemcitabine + BCG trial in NMIBC

December 10th 2025

Latest CME

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Scott T. Tagawa, MD, MS, FACP, FASCO; Kate Baxstrom, MD

DSUI Urology on the Beach

In-Person Event

DSUI Urology on the Beach

January 16-18, 2026

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Jason M. Hafron, MD

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Aaron D. Berger, MD

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Stacy Loeb, MD, MSc, PhD (Hon)

Trending on Urology Times

Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men

FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC

FDA approves zoliflodacin for uncomplicated urogenital gonorrhea

FDA approves first-line Zenflow system for the treatment of BPH

EMA recommends conditional approval of Anktiva in BCG-unresponsive NMIBC

© 2025 MJH Life Sciences^®

All rights reserved.